相关实验视频

Updated: May 22, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

聚达丁的多目标生物作用在预防伪风疹急性发作方面

Chiara Baggio¹, Paola Galozzi², Amelia Damasco¹

¹Rheumatology Unit, Department of Medicine-DIMED, University of Padova, Padova, Italy.

Frontiers in molecular biosciences

|March 14, 2025

概括

聚达丁 (PD) 防止小鼠对酸铁 (CPP) 晶体的炎症反应,保护关节和肌肉. 它的抗炎作用包括调节白细胞迁移和通过SIRT1激活减少促炎媒介.

科学领域:

生物化学生物化学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

在之前的研究中,聚达丁 (PD) 已经证明了对酸铁 (CPP) 水晶诱导的关节炎的保护作用.
了解PD抗炎作用的潜在机制对于其治疗发展至关重要.

研究的目的:

阐明聚达丁 (PD) 对酸铁 (CPP) 水晶诱导的关节炎施加抗炎作用的分子机制.
研究SIRT1和白细胞迁移途径在PD治疗作用中的作用.

主要方法:

通过CPP晶体注射诱导了小鼠的急性关节炎;动物接受了PD或胆固醇的预防性治疗.
使用了组织学分析,肌肉强度测试,蛋白质阵列和体外测试 (单细胞刺激,化疗).
使用特定抑制剂和ELISA来评估炎症调解剂,白细胞迁移和SIRT1参与.

主要成果:

治疗PD显著减少了由CPP晶体引起的关节胀和关节和腹肌肌炎症损伤.
在体外,PD调节了炎症途径,包括白细胞迁移和血管生成,并减少了促炎细胞因子和VEGF.
PD的抗炎作用与SIRT1激活和抑制CCR-1有关,这减少了单细胞激活和PBMCs迁移.

结论:

聚达丁 (PD) 有效地预防小鼠对CPP晶体的炎症反应,保持关节和肌肉的完整性.
PD的抗炎性质通过调节白细胞迁移和抑制促炎媒介来调节,在SIRT1激活中发挥关键作用.

关键词:

酸铁酸盐晶体中的.结晶诱导的炎症引起的炎症.这是一种炎症炎症炎症炎症.介质素-1ββ的使用.聚达丁是一种多元素.

更多相关视频

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

相关概念视频

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Antihypertensive Drugs: Action of Diuretics

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drug Distribution: Tissue Binding

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...